China’s reopening would pose both upside and downside risks to the country’s economy, Albert Park, chief economist at the Asian Development Bank said.
Continue readingCategory Archives: Uncategorized
Asia’s year in review: Who had it good — and who had it bad — in 2022
With hopes that Covid is in retreat and that inflation will moderate in the year ahead, we take a last look at who had it […]
Continue readingSatellite imagery venture Planet delivers record quarter, sees annual revenue nearing $200 million
Planet delivered record results for the third quarter and forecast nearly $200 million in annual revenue.
Continue reading‘Avatar: The Way of Water’ could be heading for a $175 million box office opening
The long-awaited sequel “Avatar: The Way of Water” is set to snare between $150 million and $175 million domestically during its opening weekend.
Continue readingLong Covid has contributed to more than 3,500 deaths in the U.S. since start of pandemic, CDC says
The report may underestimate long Covid deaths because clinical guidance on how to identify and report the condition has changed over time.
Continue readingU.S. soccer journalist Grant Wahl died of an aortic aneurysm while covering World Cup in Qatar, his wife says
Days before Wahl collapsed in Qatar, he had said that he’d been ill and that medical personnel had told him he likely had bronchitis.
Continue readingMortgage demand inches higher as interest rates move lower
Borrowers are finally reacting to lower mortgage rates, boosting demand for both refinances and loans to purchase homes.
Continue reading‘Harry & Meghan’ becomes Netflix’s biggest-ever documentary debut
Netflix’s documentary series about Britain’s Prince Harry and his wife, Meghan, has become the streaming platform’s biggest documentary debut yet.
Continue readingJim Cramer’s Investing Club meeting Wednesday: Fed decision, Qualcomm, Eli Lilly
The Investing Club holds its “Morning Meeting” every weekday at 10:20 a.m. ET.
Continue readingBuy this little-known and underappreciated biopharma stock with nearly 60% upside, Goldman Sachs says
Investors should consider putting money in this pharmaceutical stock poised to rally as it offers more clarity on its epilepsy drug, Goldman Sachs says.
Continue reading